Benzinga | Aug 5, 2020 04:14PM EDT

PTC Therapeutics Q2 EPS $(2.78) May Not Compare To $(1.30) Estimate, Sales $75.24M Miss $82.78M Estimate

PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(2.78) per share which missed the analyst consensus estimate of $(1.30) by 113.85 percent. This is a 270.67 percent decrease over losses of $(0.75) per share from the same period last year. The company reported quarterly sales of $75.24 million which missed the analyst consensus estimate of $82.78 million by 9.11 percent. This is a 12.02 percent decrease over sales of $85.52 million the same period last year.